Loading…
Prescription Drug Affordability Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
69pct
29d open
vs 7,255 other HR bills in the 110th — cohort avg 47d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (3)
2008 · second_quarter · Medicare/Medicaid
In support of Drug Reimportation: H.R. 194 and H.R. 380, In support of Medicare Part D Improvement: H.R. 2056, In support of Medicare Part B Means Testing Elimination: H.R. 4330
Client expense: $50,000 · Firm income: Not reported
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: HOUSE OF REPRESENTATIVES
2008 · third_quarter · Medicare/Medicaid
In support of Drug Reimportation: H.R. 194 and H.R. 380, In support of Medicare Part D Improvement: H.R. 2056, In support of Medicare Part B Means Testing Elimination: H.R. 4330
Client expense: $40,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES
2008 · fourth_quarter · Medicare/Medicaid
In support of Drug Reimportation: H.R. 194, and H.R. 380; In support of Medicare Part D Improvement: H.R. 2056; In support of Medicare Part B Means Testing Elimination: H.R. 4330; In support of Social Security Notch Reform: H.R. 368
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES
2008 · fourth_quarter · Medicare/Medicaid
In support of Drug Reimportation: H.R. 194 and H.R. 380, In support of Medicare Part D Improvement: H.R. 2056, In support of Medicare Part B Means Testing Elimination: H.R. 4330
Client expense: $40,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2008 · third_quarter · Medicare/Medicaid
In support of Drug Reimportation: H.R. 194, H.R. 380 In support of Medicare Part D Improvement: H.R. 2056 In opposition of Prescription Drug Asset Test: H.R. 1536
Client expense: $40,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES
2008 · third_quarter · Medicare/Medicaid
In support of Drug Reimportation: H.R. 194, H.R. 380, S. 242, S. 251; In support of Medicare Part D Improvement: H.R. 2056; In support of Prescription Drug Asset Test: H.R. 1536; In support of Social Security Notch Reform: H.R. 368, S.Res.363
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2008 · second_quarter · Medicare/Medicaid
In support of Drug Reimportation: H.R. 194, H.R. 380 In support of Medicare Part D Improvement: H.R. 2056 In opposition of Prescription Drug Asset Test: H.R. 1536
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES
2008 · second_quarter · Medicare/Medicaid
In support of Drug Reimportation: H.R. 194, H.R. 380, S. 242, S.251; In support of Medicare Part D Improvement: H.R. 2056; In support of Prescription Drug Asset Test: H.R. 1536; In support of Social Security Notch Reform: H.R. 368, S.Res. 363
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2008 · first_quarter · Medicare/Medicaid
In support of Drug Reimportation: H.R. 194, H.R. 380, S. 242, S. 251, Medicare Part D Improvement: H.R. 2056, Prescription Drug Assest Test: H.R. 1536
Client expense: $50,000 · Firm income: Not reported
2008 · first_quarter · Medicare/Medicaid
In support of Drug Reimportation: H.R. 194, H.R. 380, S. 242, S. 251; In support of Medicare Part D Improvement: H.R. 2056; In support of Prescription Drug Asset Test: H.R. 1536; In support of Social Security Notch Reform: H.R. 368, S.Res. 363
Client expense: Not reported · Firm income: $40,000
2008 · first_quarter · Medicare/Medicaid
In support of Drug Reimportation: H.R. 194, H.R. 380, S. 242, S. 251, Medicare Part D Improvement: H.R. 2056, Prescription Drug Assest Test: H.R. 1536
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2007 · year_end · Health Issues
Issues related to the PDUFA reauthorization Issues related to drug importation (Prescription Drug Affordability Act, H.R. 194, Pharmaceutical Market Access and Safety Drug Act, S. 242, H.R. 380) Issues related to financing of vaccine infrastructure and drug pricing in DOD Authorization Act Issues relating to use of thimarisol in vaccines
Client expense: Not reported · Firm income: $120,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2007 · year_end · Medicare/Medicaid
In support of Drug Reimportation (H.R. 194, H.R. 380), In support of Medicare Part D Improvement (H.R. 2056), in support of repealing the prescription drug asset test (H.R. 1536)
Client expense: $80,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES
2007 · year_end · Medicare/Medicaid
In support of Drug Reimportation (H.R. 194, H.R. 380), In support of Medicare Part D Improvement (H.R. 2056), In support of repealing the prescription drug asset test (H.R. 1536)
Client expense: $80,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES
2007 · mid_year · Medicare/Medicaid
In support of Drug Reimportation (H.R. 194, H.R. 380), In support of Medicare Part D Improvement (H.R. 2056), In support of repealing the prescription drug asset test (H.R. 1536)
Client expense: $80,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES
2007 · year_end · Health Issues
Issues related to PDUFA (The Prescription Drug User Fee Authorization Act) Issues related to drug importation (Prescription Drug Affordability Act/H.R. 194 and Pharmaceutical Market Access and Safety Drug Acts/S. 242, H.R. 380)
Client expense: Not reported · Firm income: $90,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2007 · year_end · Medicare/Medicaid
In support of Drug Reimportation: H.R. 194, H.R. 380, S. 242, S. 251; In support of Medicare Part D Improvement: H.R. 2056; In support of Prescription Drug Asset Test: H.R. 1536
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2007 · mid_year · Medicare/Medicaid
In support of Drug Reimportation: H.R. 194, H.R. 380, S. 242, S. 251; In support of Medicare Part D Improvement: H.R. 2056; In support of Prescription Drug Asset Test: H.R. 1536
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2007 · year_end · Medicare/Medicaid
In support of Drug Reimportion: H.R. 194, H.R. 380, S. 242, S. 251, Medicare Part D Improvement: H.R. 2056, Prescription Drug Asset Test: H.R. 1536
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2007 · year_end · Health Issues
Issues related to PDUFA (The Prescription Drug User Fee Authorization Act) Issues related to drug importation (Prescription Drug Affordability Act/H.R. 194 and Pharmaceutical Market Access and Safety Drug Acts/S. 242, H.R. 380)
Client expense: Not reported · Firm income: $90,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2007 · year_end · Health Issues
Issues related to PDUFA (The Prescription Drug User Fee Authorization Act) Issues related to drug importation (Prescription Drug Affordability Act/H.R. 194 and Pharmaceutical Market Access and Safety Drug Acts/S. 242, H.R. 380)
Client expense: Not reported · Firm income: $90,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2007 · mid_year · Health Issues
Issues related to PDUFA (The Prescription Drug User Fee Authorization Act) Issues related to drug importation (Prescription Drug Affordability Act/H.R. 194 and Pharmaceutical Market Access and Safety Drug Acts/S. 242, H.R. 380)
Client expense: Not reported · Firm income: $90,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2007 · year_end · Health Issues
Issues relating to use of thimarisol in vaccines Issues related to the PDUFA reauthorization Issues related to drug importation (Prescription Drug Affordability Act, H.R. 194, Pharmaceutical Market Access and Safety Drug Act, S. 242, H.R. 380) Issues related to financing of vaccine infrastructure and drug pricing in DOD Authorization Act
Client expense: Not reported · Firm income: $120,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2007 · mid_year · Health Issues
Issues related to PDUFA (The Prescription Drug User Fee Authorization Act) Issues related to drug importation (Prescription Drug Affordability Act/H.R. 194 and Pharmaceutical Market Access and Safety Drug Acts/S. 242, H.R. 380)
Client expense: Not reported · Firm income: $90,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2007 · mid_year · Health Issues
issues related to PDUFA (the Prescription Drug User Fee Authorization Act) issues related to drug importation (Prescription Drug Affordability Act/H.R. 194 and Pharmaceutical Market Access and Safety Drug Act/S. 242, H.R. 380)
Client expense: Not reported · Firm income: $90,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2007 · mid_year · Health Issues
issues related to the PDUFA reauthorization (Prescription Drug User Fee Authorization Act) issues related to drug importation (Prescription Drug Affordability Act, H.R. 194, Pharmaceutical Market Access and Safety Drug Act, S. 242, H.R. 380)
Client expense: Not reported · Firm income: $120,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2007 · mid_year · Medicare/Medicaid
In support of Drug Reimportation: H.R. 194, H.R. 380, S. 242, S. 251, Medicare Part D Improvement: H.R. 2056, Prescription Drug Assest Test: H.R. 1536
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE